FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2542015896> ?p ?o ?g. }

• W2542015896 abstract "Abstract Background: Outcomes of therapy for adult population diagnosed with acute lymphoblastic leukemia (ALL) remain unsatisfactory. Chemotherapy with or without bone marrow transplant (BMT) is the mainstay of treatment. We sought to describe the outcomes of chemotherapy in our population of adults with ALL who were not eligible for bone marrow transplant due to socio-economic reasons. Methods: Data from 50 patients (pts) with ALL over an 8-year period were studied as a retrospective cohort for clinical presentation, response, remission duration and long-term survival. Clinical and survival data were analyzed via Student’s T test and Fisher’s exact test. Time to relapse was analyzed with Kaplan-Meier life table analyses and Log Rank test. Results: There were 16 (32%) women and 34 (68%) men diagnosed with ALL. Median age at diagnosis was 31 years. Hispanics were the majority group with 27 pts (54%), African Americans 11 (22%), Caucasians 8 (16%), and Asian 4 (8%). B precursor ALL was present in 39 pts (78%), T precursor ALL in 8 (16%), and Burkitt’s leukemia in 3 (6%). Cytogenetics were available in 42 pts (84%): 29 pts (58%) were intermediate risk, 12 (24%) poor risk, and 1(2%) good risk. Ph chromosome was present in 6 pts (12%). A WBC above 30,000/dL was seen in 13 pts (25.49%). Myeloid markers were present in 9 (17.64%), CD10 in 45 (88.23%), and CD34 in 34 (66.6%) pts. Four pts (7.84%) had CNS disease at presentation and 3 (5.9%) had mediastinal disease. Based on age, WBC count, cytogenetics, and CNS disease at diagnosis, there were 28 high-risk pts (56%) and 22 standard-risk pts (44%). Majority of pts 38 (76%) received a 4-drug induction chemotherapy (BFM protocol). Hyper-CVAD, and CALGB protocols were used in 6 pts each (12%). A total of 42 pts (84%) achieved remission after first induction chemotherapy. There were 3 deaths (6%) and 5 (10%) nonresponders (NR). After the induction protocol, 19 pts remained in remission but 21 pts (50%) relapsed. Median time to first relapse (TTR) was 12 months. Relapsed pts were re-induced with 2nd line chemotherapy: Hyper-CVAD regimen in 10 pts (47.6%), BFM protocol in 4 (19%), and 33% with other regimens. Eleven pts (52.3%) entered a 2nd remission, 3 died, and 7 NR. Out of 11 pts who achieved a second remission, 5 pts later relapsed, 1 was still in remission at the last follow up, 2 underwent BMT and 3 were lost to follow up. TTR was analyzed according to age, gender, ethnicity, immunophenotype, cytogenetics, WBC count, presence of CD10, CD34, myeloid markers and induction protocol and no significant differences were found. Median overall survival was 16 months (range 1–97 months). Significant differences in survival were found with regards to cytogenetics (poor vs. intermediate risk, p= 0.027), presence of Ph chromosome (p= 0.0002), CNS disease at diagnosis (p= 0.0046), and response to first chemotherapy (p= 0.0032). There were no differences in overall survival according to age, gender, Hispanics vs. other ethnic groups, immunophenotype (B vs. T ALL), WBC count, presence of CD10, CD34, and myeloid markers. Also, the choice of chemotherapy regimen did not impact survival significantly. Conclusions: This cohort of patients revealed a predominance of younger male adults (median age 31 years), Hispanics (54%) and high-risk disease (56%). Remission rate after induction was 84% and early death rate (6%), comparable to those reported in the literature. 50% of responders relapsed after a median TTR of 12 months. No factors were found to impact the TTR significantly. Median survival was 16 months lower than historical cohort (30 months). Cytogenetics, Ph +, CNS disease at diagnosis and response to chemotherapy had a significant impact on survival but not on TTR. More investigation of factors which affect long-term outcome in minority population is needed." @default.
• W2542015896 created "2016-11-04" @default.
• W2542015896 creator A5000031181 @default.
• W2542015896 creator A5019915634 @default.
• W2542015896 creator A5026436106 @default.
• W2542015896 creator A5047224567 @default.
• W2542015896 creator A5050130719 @default.
• W2542015896 creator A5057356618 @default.
• W2542015896 creator A5065510808 @default.
• W2542015896 creator A5078122185 @default.
• W2542015896 creator A5078562380 @default.
• W2542015896 creator A5079511436 @default.
• W2542015896 date "2008-11-16" @default.
• W2542015896 modified "2023-10-01" @default.
• W2542015896 title "Clinical Presentation, Risk Profiles and Outcomes of Chemotherapy without Bone Marrow Transplant in a Cohort of Minority Patients with Acute Lymphoblastic Leukemia from a Public Health Hospital" @default.
• W2542015896 doi "https://doi.org/10.1182/blood.v112.11.3958.3958" @default.
• W2542015896 hasPublicationYear "2008" @default.
• W2542015896 type Work @default.
• W2542015896 sameAs 2542015896 @default.
• W2542015896 citedByCount "0" @default.
• W2542015896 crossrefType "journal-article" @default.
• W2542015896 hasAuthorship W2542015896A5000031181 @default.
• W2542015896 hasAuthorship W2542015896A5019915634 @default.
• W2542015896 hasAuthorship W2542015896A5026436106 @default.
• W2542015896 hasAuthorship W2542015896A5047224567 @default.
• W2542015896 hasAuthorship W2542015896A5050130719 @default.
• W2542015896 hasAuthorship W2542015896A5057356618 @default.
• W2542015896 hasAuthorship W2542015896A5065510808 @default.
• W2542015896 hasAuthorship W2542015896A5078122185 @default.
• W2542015896 hasAuthorship W2542015896A5078562380 @default.
• W2542015896 hasAuthorship W2542015896A5079511436 @default.
• W2542015896 hasConcept C126322002 @default.
• W2542015896 hasConcept C141071460 @default.
• W2542015896 hasConcept C167135981 @default.
• W2542015896 hasConcept C187212893 @default.
• W2542015896 hasConcept C2776694085 @default.
• W2542015896 hasConcept C2778336483 @default.
• W2542015896 hasConcept C2908647359 @default.
• W2542015896 hasConcept C71924100 @default.
• W2542015896 hasConcept C72563966 @default.
• W2542015896 hasConcept C99454951 @default.
• W2542015896 hasConceptScore W2542015896C126322002 @default.
• W2542015896 hasConceptScore W2542015896C141071460 @default.
• W2542015896 hasConceptScore W2542015896C167135981 @default.
• W2542015896 hasConceptScore W2542015896C187212893 @default.
• W2542015896 hasConceptScore W2542015896C2776694085 @default.
• W2542015896 hasConceptScore W2542015896C2778336483 @default.
• W2542015896 hasConceptScore W2542015896C2908647359 @default.
• W2542015896 hasConceptScore W2542015896C71924100 @default.
• W2542015896 hasConceptScore W2542015896C72563966 @default.
• W2542015896 hasConceptScore W2542015896C99454951 @default.
• W2542015896 hasLocation W25420158961 @default.
• W2542015896 hasOpenAccess W2542015896 @default.
• W2542015896 hasPrimaryLocation W25420158961 @default.
• W2542015896 hasRelatedWork W2241382955 @default.
• W2542015896 hasRelatedWork W2370999289 @default.
• W2542015896 hasRelatedWork W2417044364 @default.
• W2542015896 hasRelatedWork W2531034485 @default.
• W2542015896 hasRelatedWork W2535500798 @default.
• W2542015896 hasRelatedWork W2549582149 @default.
• W2542015896 hasRelatedWork W2555070547 @default.
• W2542015896 hasRelatedWork W2558854175 @default.
• W2542015896 hasRelatedWork W2564514339 @default.
• W2542015896 hasRelatedWork W2575449152 @default.
• W2542015896 hasRelatedWork W2587669109 @default.
• W2542015896 hasRelatedWork W2591261245 @default.
• W2542015896 hasRelatedWork W2979778709 @default.
• W2542015896 hasRelatedWork W2979796411 @default.
• W2542015896 hasRelatedWork W2980228670 @default.
• W2542015896 hasRelatedWork W2980449625 @default.
• W2542015896 hasRelatedWork W2991795416 @default.
• W2542015896 hasRelatedWork W3032600680 @default.
• W2542015896 hasRelatedWork W3157182593 @default.
• W2542015896 hasRelatedWork W378987734 @default.
• W2542015896 isParatext "false" @default.
• W2542015896 isRetracted "false" @default.
• W2542015896 magId "2542015896" @default.
• W2542015896 workType "article" @default.